Edition:
United States

Swedish Orphan Biovitrum AB (publ) (SOBIV.ST)

SOBIV.ST on Stockholm Stock Exchange

257.70SEK
7:08am EDT
Change (% chg)

-2.50kr (-0.96%)
Prev Close
260.20kr
Open
260.60kr
Day's High
261.80kr
Day's Low
257.30kr
Volume
183,563
Avg. Vol
876,792
52-wk High
299.60kr
52-wk Low
107.40kr

Latest Key Developments (Source: Significant Developments)

SOBI Q1 Beats Forecasts, Raises Full-Year Profit, Revenue Outlook
Thursday, 26 Apr 2018 02:00am EDT 

April 26 (Reuters) - Swedish Orphan Biovitrum AB (SOBI) ::SAYS SOBI NOW EXPECTS TOTAL REVENUES FOR FULL-YEAR TO BE IN RANGE OF SEK 7,900-8,100 M (7,500-7,700).SAYS GROSS MARGIN IS EXPECTED TO BE AT LEAST 70 PER CENT (UNCHANGED).Q1 - EBITA INCREASED WITH 90 PER CENT TO SEK 771 M (406).SAYS SOBI NOW EXPECTS EBITA FOR FULL-YEAR TO BE IN RANGE OF SEK 2,800-3,000 M (2,500-2,700).Q1 - TOTAL REVENUES GREW 41 PER CENT COMPARED TO Q1 2017 AND AMOUNTED TO SEK 1,964 M.REUTERS POLL: SOBI Q1 EBITA WAS SEEN AT 668 MILLION SEK, REVENUES AT 1,857 MILLION.  Full Article

Sobi launches Ravicti in Europe ‍​
Wednesday, 21 Mar 2018 03:00am EDT 

March 21 (Reuters) - Swedish Orphan Biovitrum ::SAYS LAUNCHES RAVICTI IN EUROPE AND ADVANCES THE CARE FOR PATIENTS WITH UREA CYCLE DISORDERS .SAYS HAS GAINED REIMBURSEMENT FOR RAVICTI®, A NEW THERAPY OPTION FOR THE TREATMENT OF PATIENTS WITH UREA CYCLE DISORDERS (UCDS) IN SEVERAL EU MEMBER STATES AND EEA-COUNTRIES.SAYS SWEDEN, DENMARK, AUSTRIA AND GERMANY ARE THE FIRST COUNTRIES TO LAUNCH, FOLLOWED BY UK, SPAIN AND THE NETHERLANDS.‍​.  Full Article

Sobi raises outlook as Q3 core profit beats expectations
Wednesday, 25 Oct 2017 02:00am EDT 

Oct 25 (Reuters) - Swedish Orphan Biovitrum Ab (Publ) :Swedish orphan biovitrum q3 ‍ebita was sek 536 m (282)​.Swedish orphan biovitrum says ‍sobi now expects total revenues for full year to be in range of sek 6,300 to 6,400 m (6,100-6,200)​.Swedish orphan biovitrum says ‍gross margin is expected to be around 70 per cent​.Swedish orphan biovitrum q3 ‍total revenue was sek 1,601 m​.Swedish orphan biovitrum says ‍now expects ebita for full year to be in range of sek 1,900 to 2,000 m (1,700-1,800)​.Swedish orphan biovitrum says ‍growth strategy has been designed to capitalise on substantial potential in haemophilia​.Swedish orphan biovitrum says ‍based on this solid platform we will further balance business with a broader specialty care portfolio to ensure a sustainable company in both short and long-term​.Swedish orphan biovitrum says to decentralise decision making towards the country organisations, resource allocation to support this strategic initiative will be reflected accordingly‍​.Swedish orphan biovitrum says we are rebalancing our geographical footprint in our existing markets by, among other things, scaling and developing our north american franchise‍​.Swedish orphan biovitrum says the strengthening of our late stage research and development pipeline is another key area of focus going forward‍​.Reuters poll: sobi q3 ebita was seen at 509 million sek, revenues at 1,636 million.  Full Article

Sobi Q2 EBITA falls, raises 2017 guidance
Wednesday, 19 Jul 2017 02:00am EDT 

July 19 (Reuters) - Swedish Orphan Biovitrum :Swedish orphan biovitrum Q2 total revenue was SEK 1,639 mln (1,469).Swedish orphan biovitrum Q2 product revenue was SEK 1,443 mln (1,288).Swedish orphan biovitrum Q2 gross margin was 71 percent (72).Q2 EBITA was SEK 492 mln (550).Says now expects total revenues for full year in range of SEK 6,100 to 6,200 mln (5,800-6,000).Says gross margin is now expected to be around 70 percent (66-68).Says now expects EBITA for full year to be in range of SEK 1,700 to 1,800 mln (1,600-1,700).  Full Article

Sobi ends discussions to sell Partner Products business area
Monday, 5 Jun 2017 09:45am EDT 

June 5 (Reuters) - Swedish Orphan Biovitrum :Sobi keeps the Partner Products business area as an integral part of the company.Says discussions regarding a potential sale of Partner Products business area, which Sobi confirmed were ongoing in a press release on 3 february 2017, have been terminated.  Full Article

Sobi appoints Guido Oelkers as new CEO
Thursday, 4 May 2017 02:00am EDT 

May 4 (Reuters) - Swedish Orphan Biovitrum AB (Publ) :Guido Oelkers appointed President and CEO at Sobi.Oelkers joins Sobi from his previous role as CEO at BSN Medical GmbH.Says Oelkers has extensive experience from pharmaceutical and health care companies including a role as President and CEO of the Swedish medtech company Gambro.  Full Article

Sobi Q1 EBITA SEK 406 mln, repeats outlook
Friday, 28 Apr 2017 02:00am EDT 

April 28 (Reuters) - Swedish Orphan Biovitrum :Q1 total revenue was SEK 1,396 mln (1,273).Says Q1 revenues grew 10 per cent overall, and by 47 percent adjusted for the one-time credit of SEK 322 million received in Q1 2016. .Q1 product revenue was SEK 1,269 mln (1,108).Q1 gross margin was 74 per cent (74).Q1 EBITA was SEK 406 mln (502).Says outlook for 2017 is unchanged.  Full Article

Sobi CEO sees broad interest in Partner Products platform
Thursday, 16 Feb 2017 02:27am EST 

Swedish Orphan Biovitrum AB CEO Geoffrey McDonough to reporters: says there is broad interest in the platform of the partner products division which sobi is considering selling . says his personal view is it would be premature to pay dividend for 2017 as company still in an active development phase Further company coverage: [SOBIV.ST] (Reporting By Anna Ringstrom) ((Anna.Ringstrom@thomsonreuters.com;)).  Full Article

Sobi Q4 EBITA lags expectations
Thursday, 16 Feb 2017 02:00am EST 

Swedish Orphan Biovitrum : Q4 ebita of sek 210 m (90) . Q4 total revenue of sek 1,292 m (814), an increase of 59 per cent (54 per cent at cer) . Q4 gross margin of 67 per cent (64) . Reuters poll: sobi q4 ebita was seen at sek 271 million, revenues at 1,278 million . says expects revenues for full year 2017 to be in range of sek 5,800 to 6,000 m . says 2017 gross margin is expected to be in range of 66 to 68 per cent .says expects ebita for full year to be in range of sek 1,600 to 1,700 m.  Full Article

Sobi confirms divestment discussions, shares halted
Friday, 3 Feb 2017 08:23am EST 

Swedish Orphan Biovitrum : Says confirms that company is in discussions with a private equity firm regarding a possible sale of its partner products business area excluding Kineret and Orfadin. . Says discussions may or may not lead to an agreement . "We have noted specific information in the market regarding a possible sale of Sobi Partner Products. We confirm that we are in discussions which may or may not lead to an agreement", said Geoffrey McDonough, CEO and President .Trade in the Sobi share was suspended at 13:16 GMT.  Full Article

CORRECTED-Sweden's Sobi buys rights for emapalumab drug, strengthening inflammation business

STOCKHOLM, July 20 Drugmaker Swedish Orphan Biovitrum (Sobi) said on Friday it had reached an exclusive licensing deal with Swiss firm Novimmune SA for the perpetual global rights to emapalumab, a late-stage orphan drug candidate for the treatment of primary Haemophagocytic lymphohistiocytosis.